These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17351422)

  • 1. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates.
    Rose S; Scheller DK; Breidenbach A; Smith L; Jackson M; Stockwell K; Jenner P
    Behav Pharmacol; 2007 Mar; 18(2):155-60. PubMed ID: 17351422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
    Stockwell KA; Scheller D; Rose S; Jackson MJ; Tayarani-Binazir K; Iravani MM; Smith LA; Olanow CW; Jenner P
    Exp Neurol; 2009 Oct; 219(2):533-42. PubMed ID: 19619533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets.
    Stockwell KA; Scheller DK; Smith LA; Rose S; Iravani MM; Jackson MJ; Jenner P
    Exp Neurol; 2010 Jan; 221(1):79-85. PubMed ID: 19833125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
    Lincoln L; Fisher R; Jackson MJ; Jenner P; Neumeyer J; Sromek AW; Lees AJ; Rose S
    Mov Disord; 2016 Sep; 31(9):1381-8. PubMed ID: 27133947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
    Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Hansard MJ; Jackson MJ; Smith LA; Rose S; Jenner P
    Behav Pharmacol; 2011 Jun; 22(3):269-74. PubMed ID: 21522056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
    Eskow Jaunarajs KL; Standaert DG; Viegas TX; Bentley MD; Fang Z; Dizman B; Yoon K; Weimer R; Ravenscroft P; Johnston TH; Hill MP; Brotchie JM; Moreadith RW
    Mov Disord; 2013 Oct; 28(12):1675-82. PubMed ID: 24014074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
    Scheller D; Chan P; Li Q; Wu T; Zhang R; Guan L; Ravenscroft P; Guigoni C; Crossman AR; Hill M; Bezard E
    Exp Neurol; 2007 Feb; 203(2):415-22. PubMed ID: 17045989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
    Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
    Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
    Olanow CW; Standaert DG; Kieburtz K; Viegas TX; Moreadith R
    Mov Disord; 2020 Jun; 35(6):1055-1061. PubMed ID: 32251552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.
    Smith LA; Jackson MJ; Al-Barghouthy G; Jenner P
    J Neural Transm (Vienna); 2002 Feb; 109(2):123-40. PubMed ID: 12075853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
    Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.